Related Experiment Video
Updated: Feb 21, 2026

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
Published on: October 6, 2023
Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access
Delphi G M Coppens1, Marie L De Bruin1,2, Hubert G M Leufkens1
1Utrecht/WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Abstract:
Gene- and cell-based therapies (GCTs) offer potential new treatment options for unmet medical needs. However, the use of conventional regulatory requirements for medicinal products to approve GCTs may impede patient access and therapeutic innovation. Furthermore, requirements differ between jurisdictions, complicating the global regulatory landscape. We provide a comparative overview of regulatory requirements for GCT approval in five jurisdictions and hypothesize on the consequences of the observed global differences on patient access and therapeutic innovation.
More Related Videos
Related Concept Videos
Gene Therapy
Drug Products: Biologics, Biosimilars and Interchangeables
What is Genetic Engineering?
Microorganisms in Medicine and Therapeutics
Pharmacogenomics: Identification of New Drug Targets
Stem Cell Culture

